


[illegible]



FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
 (Use several sheets if necessary)

Sheet 1 of 7

ATTORNEY DOCKET NO.	SERIAL NO.
01507/1/US; 027880A/USA; (6794-000177/US)	10/803,145
APPLICANT	
Karen Siebert	
FILING DATE	GROUP
March 17, 2004	1617

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.	RI	4,233,299	11/10/1980	Trummlitz et al.	514/226.5	
2.		4,885,367	12/5/1989	Yoshikawa et al.	546/216	
3.		5,344,991	9/6/1994	Reitz et al.	568/34	
4.		5,466,823	11/14/1995	Talley et al.	548/377.1	
5.		5,474,995	12/12/1995	Ducharme et al.	514/241	
6.		5,521,207	5/28/1996	Graneto, Matthew J.	514/406	
7.		5,633,272	5/27/1997	Talley et al.	514/378	
8.		5,760,068	6/2/1998	Talley et al.	514/403	
9.		5,840,924	11/24/1998	Desmond et al.	549/323	
10.		5,932,598	8/3/1999	Talley et al.	514/341	
11.		5,945,539	8/31/1999	Haruta et al.	548/235	
12.		5,958,978	9/28/1999	Yamazaki et al.	514/567	
13.		5,981,576	11/9/1999	Belley et al.	514/473	
14.		5,994,379	11/30/1999	Bayly et al.	514/367	
15.		5,994,381	11/30/1999	Haruta et al.	514/374	
16.		6,001,843	12/14/1999	Dube et al.	514/277	
17.		6,002,014	12/14/1999	Haruta et al.	548/235	
18.		6,004,948	12/21/1999	Blaschke et al.	514/155	
19.		6,020,343	2/1/2000	Belley et al.	514/309	
20.	↓	6,028,202	2/22/2000	Connolly et al.	548/376.1	
21.	RI	6,034,256	3/7/2000	Carter et al.	549/456	

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**
(Use several sheets if necessary)

Sheet 2 of 7

ATTORNEY DOCKET NO.

01507/1/US; 027880A/USA;
(6794-000177/US)

SERIAL NO.

10/803,145

APPLICANT

Karen Siebert

FILING DATE

March 17, 2004

GROUP

1617

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
22.	RI	6,040,320	3/21/2000	Beers et al.	514/341	
23.		6,040,450	3/21/2000	Davies et al.	546/256	
24.		6,046,217	4/4/2000	Friesen et al.	514/347	
25.		6,046,236	4/4/2000	Hamanaka et al.	514/535	
26.		6,057,319	5/2/2000	Black et al.	514/242	
27.		6,071,936	6/6/2000	Dube et al.	514/334	
28.		6,077,850	6/20/2000	Dube et al.	514/311	
29.		6,077,868	6/20/2000	Cook et al.	514/560	
30.		6,077,869	6/20/2000	Sui et al.	514/615	
31.		6,080,876	6/27/2000	Dorziotis et al.	549/319	
32.		6,083,969	7/4/2000	Ferro et al.	514/403	
33.		6,127,545	10/3/2000	Pye et al.	546/286	
34.		6,130,334	10/10/2000	Pye et al.	546/286	
35.		6,133,292	10/17/2000	Wang et al.	514/336	
36.		6,136,831	10/24/2000	Aotsuka et al.	514/367	
37.		6,140,515	10/31/2000	Chen et al.	549/324	
38.		6,153,787	11/28/2000	Rossen et al.	560/187	
39.		6,169,188	1/2/2001	Belley et al.	549/330	
40.		6,180,651	1/30/2001	Nicolai et al.	514/336	
41.	↓	6,204,387	3/20/2001	Davies et al.	546/315	

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**
(Use several sheets if necessary)

Sheet 3 of 7

ATTORNEY DOCKET NO.

SERIAL NO.

01507/1/US; 027880A/USA;
(6794-000177/US)

10/803,145

APPLICANT

Karen Siebert

FILING DATE

March 17, 2004

GROUP

1617

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
42.	RI	6,222,048	4/24/2001	Black et al.	549/60	
43.		6,239,137	5/29/2001	Karmali et al.	514/274	
44.		6,239,173	5/29/2001	Wang et al.	514/473	
45.		6,271,253	8/7/2001	Carter et al.	514/432	
46.		6,291,523	9/18/2001	Fujimoto et al.	514/533	
47.		6,297,282	10/2/2001	Hartmann et al.	514/603	
48.		6,300,363	10/9/2001	Stevens et al.	514/415	
49.		6,303,628	10/16/2001	Nakao et al.	514/307	
50.		6,306,890	10/23/2001	Kalgutkar et al.	514/419	
51.		6,307,047	10/23/2001	Black et al.	544/240	
52.		6,310,079	10/30/2001	Okumura et al.	514/338	
53.		6,310,099	10/30/2001	Fujimoto et al.	514/567	
54.		6,329,421	12/11/2001	Prasit et al.	514/443	
55.		6,340,694	1/22/2002	Joo et al.	514/337	
56.		6,359,182	3/19/2002	Stamler et al.	568/949	
57.		6,362,209	3/26/2002	Haruta et al.	514/374	
58.		6,369,275	4/9/2002	Davies et al.	568/56	
59.		6,376,519	4/23/2002	Reddy et al.	514/341	
60.		6,395,724	5/28/2002	Judice et al.	514/183	
61.	↓	6,432,999	8/13/2002	Talley et al.	514/406	

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**
(Use several sheets if necessary)

Sheet 4 of 7

ATTORNEY DOCKET NO.

01507/1/US; 027880A/USA;
(6794-000177/US)

SERIAL NO.

10/803,145

APPLICANT

Karen Siebert

FILING DATE

March 17, 2004

GROUP

1617

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
62.	RI	6,436,967	8/20/2002	Talley et al.	514/341	
63.		6,451,794	9/17/2002	Beswick et al.	514/248	
64.		6,451,858	9/17/2002	Fujimoto et al.	514/567	
65.		6,465,509	10/15/2002	Li et al.	514/460	
66.		6,472,416	10/29/2002	Kolasa et al.	514/403	
67.		6,492,390	12/10/2002	Carter et al.	514/311	
68.		6,492,416	12/10/2002	Shin et al.	514/473	
69.		6,498,166	12/24/2002	Campbell et al.	514/300	
70.		6,512,121	1/28/2003	Talley et al.	548/111	
71.		6,515,014	2/4/2003	Talley et al.	514/438	
72.		6,518,303	2/11/2003	Crespo Crespo et al.	514/459	
73.		6,538,116	3/25/2003	Stamler et al.	534/568	
74.		6,555,563	4/29/2003	Le et al.	514/363	
75.		6,583,321	6/24/2003	Cho et al.	568/33	
76.		6,596,736	7/22/2003	Dube et al.	514/334	
77.		6,599,929	7/29/2003	Cho et al.	514/415	
78.		6,613,790	9/2/2003	Carter, Jeffery S.	514/406	
79.		2003/0165588	9/4/2003	Jia Qi et al.	424/757	
80.	↓	2003/0207897	1/25/2005	DeMello et al.	514/228.2	

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**
(Use several sheets if necessary)

Sheet 5 of 7

ATTORNEY DOCKET NO.

SERIAL NO.

01507/1/US; 027880A/USA;
(6794-000177/US)

10/803,145

APPLICANT

Karen Siebert

FILING DATE

March 17, 2004

GROUP

1617

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes No	
81.	RI	EP 0 863 134	9/9/1998	Europe	C07C317/24		
82.		EP 1 312 367	5/21/2003	Europe	A61K31/55		
83.		WO 00/23433	4/27/2000	PCT	C07D311/58		
84.		WO 00/24719	5/4/2000	PCT	C07D237/14		
85.		WO 00/25779	5/11/2000	PCT	A61K31/405		
86.		WO 02/20090	3/14/2002	PCT	A61P5/00		
87.		WO 94/15932	7/21/1994	PCT	C07D333/18		
88.		WO 94/27980	12/8/1994	PCT	C07D263/32		
89.		WO 95/00501	1/5/1995	PCT	C07D277/02		
90.		WO 95/15315	6/8/1995	PCT	C07D231/12		
91.		WO 95/15316	6/8/1995	PCT	C07D231/12		
92.		WO 96/03385	2/8/1996	PCT	C07D231/12		
93.		WO 96/03387	2/8/1996	PCT	C07D233/54		
94.		WO 96/03388	2/8/1996	PCT	C07D233/54		
95.		WO 96/03392	2/8/1996	PCT	C07D277/26		
96.		WO 96/09304	3/28/1996	PCT	C07D491/048		
97.		WO 96/16934	6/6/1996	PCT	C07C317/14		
98.		WO 96/24585	8/15/1996	PCT	C07D213/64		
99.		WO 96/25405	8/22/1996	PCT	C07D261/08		
100.	✓	WO 98/03484	1/29/1998	PCT	C07D213/34		

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**
(Use several sheets if necessary)

Sheet 6 of 7

ATTORNEY DOCKET NO.

01507/1/US; 027880A/USA;
(6794-000177/US)

SERIAL NO.

10/803,145

APPLICANT

Karen Siebert

FILING DATE

March 17, 2004

GROUP

1617

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
101.	RI	WO 98/47890	10/29/1998	PCT	C07D311/58		
102.	↓	WO 99/10331	3/4/1999	PCT	C07D237/14		
103.	↓	WO 99/10332	3/4/1999	PCT	C07D237/14		
104.	↓	WO 99/11605	3/11/1999	PCT	C07C229/42		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
105.	RI	Barnes, "Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma," Journal of Allergy and Clinical Immunology, 101(4):S427-33 (1998)
106.	↓	Barnes et al., "Efficacy and safety of inhaled corticosteroids: new developments," Am J Respiratory and Critical Care Medicine, 157:S1-S53 (1998)
107.	↓	Benet et al., "Design and Optimization of Dosage Regimens: Pharmacokinetic Data," in Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition (1996), Appendix II, pp. 1707-1711
108.	↓	Bundschuh et al., "In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor," The Journal of Pharmacology and Experimental Therapeutics, 297(1):280-290 (2001)
109.	↓	College of Physicians and Surgeons of Alberta, "Spirometry & Flow Volume Measurements: Standards and Guidelines" (December 1998)
110.	↓	Fu et al., "The induction and suppression of prostaglandin H2 Synthase (Cyclooxygenase) in Human Monocytes," Journal of Biological Chemistry, 265(28):16737-40 (1990)
111.	↓	Kirchner et al., "Evaluation of the Antiinflammatory Activity of a Dual Cyclooxygenase-2 Selective/5-Lipoxygenase Inhibitor, RWJ 63556, in a Canine Model of Inflammation," Journal of Pharmacology and Experimental Therapeutics, 282:1094-1101 (1997)
112.	↓	Needleman et al., "The Discovery and Function of COX-2," Journal of Rheumatology, Vol. 24, Suppl. 49, pages 6-8 (1997)
113.	↓	Samad et al., "Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity," Nature, 410:471-75 (2001)
114.	↓	Sterry et al., "Therapy with topical corticosteroids," Arch Dermatol Res, 284[Suppl]:S27-S29 (1992)

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE CITATION</p> <p>(Use several sheets if necessary)</p> <p>Sheet 7 of 7</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	01507/1/US; 027880A/USA; (6794-000177/US)	10/803,145
	APPLICANT	
	Karen Siebert	
	FILING DATE	GROUP
	March 17, 2004	1617

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
115.	RI	The Merck Manual, 17th edition, Sec. 6, Chapter 68, Chronic Obstructive Airway Disorders, Asthma, pages 556-568 (1999)
116.	↓	The Merck Manual, 17th edition, Sec. 6, Chapter 68, Chronic Obstructive Airway Disorders, COPD, pages 568-582 (1999)
117.	↓	The Merck Manual, 17th edition, Sec. 7, Chapter 83-85, pages 669-683 (1999)
118.	↓	Yoshimi et al., "Chemopreventive Effect of N-(2-Cyclohexyloxy-4-nitrophenyl)methane Sulfonamide (NS-398), a Selective Cyclooxygenase-2 Inhibitor, in Rat Colon Carcinogenesis Induced by Azoxymethane," Jpn J Cancer Res, 90(4):406-412 (1999)

Examiner: /Roy Issac/ (06/19/2006)	Date Considered: 06/19/2006
------------------------------------	-----------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.